Method for determining valmololone metabolite in liver microsome

Through ultra-high performance liquid chromatography-high resolution mass spectrometry technology and specific incubation system, the problem of detecting vamoloron metabolites in liver microsomes was solved, efficient and accurate identification and identification of metabolites were achieved, and new drug development and Clinical application.

CN119000948APending Publication Date: 2024-11-22SHANGHAI UNIV OF SPORT
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411264255.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively detect the metabolites of vamoloson in liver microsomes, especially in complex biological matrixes. It is difficult for conventional chromatographic separation methods to separate metabolites with similar structures, affecting the accuracy of identification.

Method used

Ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) technology combined with specific incubation systems and detection methods, including the use of nicotinamide adenine dinucleotide phosphoric acid, magnesium chloride, uridine diphosphate glucuronic acid and D-glucose Components such as acid-1.4-lactone simulate the liver metabolic environment, and chromatography and mass spectrometry are detected by vortex and centrifugation, which improves the resolution and identification accuracy of metabolites.

Benefits of technology

It has achieved efficient and accurate identification and identification of vamolodon metabolites, reduced interference from endogenous substances, improved detection sensitivity and resolution, and is suitable for metabolic research of vamolodon and other small molecule drugs, promoting New drug development and clinical application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119000948A_ABST
    Figure CN119000948A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine analysis, in particular to a method for determining a valmololone metabolite in liver microsome. The method for determining the wurmololone metabolite in the liver microsome comprises the following steps: (a) adding wurmololone into a reaction base solution for incubation; adding a terminating agent into the reaction system after the incubation is finished, so as to obtain a wurmololone metabolite; (b) carrying out vortex and centrifugation on the waumololone metabolite, and collecting a supernatant; (c) performing chromatographic detection and mass spectrometric detection on the supernate; and (d) identifying the metabolite. The method is simple and convenient to operate, simple in sample pretreatment, high in analysis speed, high in sensitivity and strong in specificity, and can be used for accurately identifying the metabolite characteristics of the valmololone in the liver microsome. The method is not only suitable for the research of the Laumololone metabolite, but also can provide technical support for the metabolism research of other small molecule drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical analysis, and in particular to a method for determining metabolites of valmorolone in liver microsomes. Background Art

[0002] In the process of modern drug development and clinical application, drug metabolism research is crucial to evaluate its safety and efficacy. Vamorolone is a new type of synthetic steroidal anti-inflammatory drug, mainly used to treat inflammatory diseases such as Duchenne muscular dystrophy (DMD). Compared with traditional glucocorticoids, vamorolone has shown broad clinical application prospects due to its unique mechanism of action and lower side effects. However, the metabolic characteristics of vamorolone in the body have not been fully clarified, and the types, structures and toxicity of its metabolites still need further study.

[0003] The liver microsome model is an important tool for studying drug metabolism in vitro, which can simulate the metabolic process of drugs in the liver. Using liver microsomes for drug metabolism research can effectively predict the metabolic pathways and products of drugs in early screening, providing a scientific basis for subsequent drug development. Since the liver microsome model contains a variety of endogenous substances, these substances will interfere in mass spectrometry analysis, which makes it difficult to detect vamocarb and its metabolites at low concentrations; in addition, vamocarb metabolites may involve a variety of phase I (such as oxidation, reduction) and phase II (such as glucuronidation, sulfation) reactions, producing metabolites with complex structures and different properties. The chemical structures of these metabolites may be very similar, and conventional chromatographic separation methods are difficult to effectively separate these metabolites, thus affecting the accuracy of their identification. At present, ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) technology has been widely used in the identification and quantitative analysis of small molecule drug metabolites due to its high sensitivity and high resolution. However, systematic analysis of vamocarb metabolites is relatively scarce, especially in complex biological matrices such as liver microsomes. Metabolite detection technology still has certain challenges.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The object of the present invention is to provide a method for determining the metabolites of valmorolone in liver microsomes. The method for determining the metabolites of valmorolone in liver microsomes has the advantages of simple operation, simple sample pretreatment, fast analysis speed, high sensitivity, strong specificity, and the ability to efficiently and accurately identify the characteristics of the metabolites of valmorolone in liver microsomes.

[0006] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0007] One aspect of the present invention relates to a method for determining the metabolites of valmorolone in liver microsomes, comprising the following steps:

[0008] (a) adding vamosone to a reaction base solution for incubation; adding a terminator to the reaction system after the incubation to obtain a vamosone metabolite;

[0009] The reaction base solution includes: nicotinamide adenine dinucleotide phosphate (NADPH), magnesium chloride, uridine diphosphoglucuronic acid (UDPGA), D-glucono-1.4-lactone and liver microsomes (pHLMs);

[0010] (b) vortexing and centrifuging the vamosaurus metabolite to collect the supernatant;

[0011] (c) subjecting the supernatant to chromatography and mass spectrometry;

[0012] (d) Identification of metabolites.

[0013] The method for determining the metabolites of vamorotone in liver microsomes is simple to operate, has simple sample pretreatment, fast analysis speed, high sensitivity and strong specificity. The method can efficiently and accurately identify the characteristics of the metabolites of vamorotone in liver microsomes. The method is not only suitable for the study of vamorotone metabolites, but also can provide technical support for the metabolic research of other small molecule drugs, thereby promoting the development and clinical application of new drugs.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] (1) The present invention uses high-quality liver microsomes, and by adjusting and improving the incubation system and reaction conditions, it can simulate the metabolic process of vamoglobin in the human liver to the greatest extent. Rapid centrifugation is used in the sample processing stage, and ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) technology is used in the analysis stage to improve the sensitivity and separation of vamoglobin metabolite detection, effectively eliminate the interference of endogenous substances, and ensure the accurate identification and analysis of metabolites, which is of great significance for in-depth research on drug active products and their mechanisms of action.

[0016] (2) The present invention uses a C18-PFP (pentafluorophenyl) chromatographic column to improve the selectivity and separation of vamosinolone and its metabolites, thereby improving the detection accuracy; by improving the composition and gradient program of the mobile phase, the separation time can be better controlled to ensure that the peak shape of the metabolites is sharper and the separation is higher, avoiding peak overlap and signal interference. High resolution and multiple scanning modes (full scan and DDA mode) are used in mass spectrometry detection to provide detailed metabolite information, and the high resolution setting improves the accuracy of metabolite detection and reduces the overlap and interference of mass spectrometry signals. Therefore, the present invention combines the advantages of ultra-high performance liquid phase (UHPLC) and high-resolution mass spectrometry (HRMS), and has the characteristics of high efficiency, accuracy, and good sensitivity of UHPLC, and can separate and analyze complex mixture samples, and also has the high sensitivity and high resolution characteristics of high-resolution mass spectrometry, and can separate and analyze complex mixture samples, and also has the high sensitivity and high selectivity characteristics of mass spectrometry, and provides accurate molecular weight and rich structural feature information for the identification of unknown compounds. The method of the present invention is particularly suitable for the study of small molecule drugs with complex active ingredients and low content. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1 The total ion current chromatogram of the liver microsomes and the incubation system (without vamorolone) of the present invention;

[0019] Figure 2 The total ion current chromatogram of the vamosaurus and the incubation system (without liver microsomes) of the present invention;

[0020] Figure 3 This is a total ion current chromatogram of the vamosinolone after conversion in the liver microsome incubation system of the present invention;

[0021] Figure 4 The extracted ion flow chromatogram of the metabolites M1-M10, iso-M1 and iso-M3 of vamorolone in the liver microsome incubation system of the present invention;

[0022] Figure 5 This is the metabolic pathway of vamorolone in the liver microsome incubation system of the present invention. DETAILED DESCRIPTION

[0023] The technical scheme of the present invention will be clearly and completely described below in conjunction with the accompanying drawings and specific embodiments, but it will be understood by those skilled in the art that the following described embodiments are part of embodiments of the present invention, rather than all embodiments, and are only used to illustrate the present invention, and should not be considered as limiting the scope of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If specific conditions are not specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0024] One aspect of the present invention relates to a method for determining the metabolites of valmorolone in liver microsomes, comprising the following steps:

[0025] (a) adding vamosone to a reaction base solution for incubation; adding a terminator to the reaction system after the incubation to obtain a vamosone metabolite;

[0026] The reaction base solution includes: nicotinamide adenine dinucleotide phosphate (NADPH), magnesium chloride, uridine diphosphoglucuronic acid (UDPGA), D-glucono-1.4-lactone and liver microsomes (pHLMs);

[0027] (b) vortexing and centrifuging the vamosaurus metabolite to collect the supernatant;

[0028] (c) subjecting the supernatant to chromatography and mass spectrometry;

[0029] (d) Identification of metabolites.

[0030] The method for determining the metabolites of vamorotone in liver microsomes is simple to operate, simple in sample pretreatment, fast in analysis speed, high in sensitivity and strong in specificity. The method can efficiently and accurately identify the metabolite characteristics of vamorotone in liver microsomes. The method is not only applicable to the study of vamorotone metabolites, but also can provide technical support for the metabolic research of other small molecule drugs, thereby promoting the development and clinical application of new drugs.

[0031] The present invention adjusts and improves the reaction conditions, determines the optimal incubation system, and establishes a simple, rapid, highly sensitive, specific, and high-throughput HC-HRMS detection method applicable to the metabolites of vamorotolone, which can efficiently and accurately identify the metabolite characteristics of vamorotolone in liver microsomes.

[0032] In the incubation reaction system, NADPH is the main electron donor in phase I metabolic reactions and is mainly used for reactions of the reduced P450 enzyme system. It provides the required reducing power for cytochrome P450 enzymes (CYP enzymes) in liver microsomes and promotes the occurrence of oxidation reactions. These oxidation reactions are key steps in drug metabolism and usually include reactions such as hydroxylation, dealkylation, and epoxidation; magnesium chloride, as a cofactor, helps stabilize nucleotides (such as NADPH) and maintain their functions. Magnesium ions also participate in the activation of related enzyme systems, especially in phosphorylation reactions. UDPGA is an important substrate in phase II metabolic reactions and participates in glucuronidation reactions; D-glucono-1,4-lactone is an inhibitor of glucuronidation reactions, which can prevent nonspecific reactions of UGT enzymes in the preparation stage. It helps stabilize the reaction conditions, ensures that UDPGA effectively participates in the metabolic reaction, and makes the reaction more specific. Liver microsomes are a commonly used tool in in vitro drug metabolism research. They are composed of fragments of the endoplasmic reticulum of liver cells and contain rich metabolic enzymes (such as cytochrome P450 enzyme system, UGT enzyme system, etc.). They can simulate the actual situation of drug metabolism in the body and help study the metabolic pathways and products of drugs in the liver.

[0033] Furthermore, in the incubation reaction system, the concentration of nicotinamide adenine dinucleotide phosphate is 2 to 10 mmoL / mL, including but not limited to any point value of 2 mmoL / mL, 4 mmoL / mL, 6 mmoL / mL, 8 mmoL / mL or 10 mmoL / mL or a range value between any two. Limiting the concentration of nicotinamide adenine dinucleotide phosphate to a certain range can ensure that the amount of metabolites generated reaches an optimal level, while avoiding nonspecific reactions caused by excessively high NADPH concentrations.

[0034] Further, in the incubated reaction system, the concentration of magnesium chloride is 2 to 10 mmoL / mL, including but not limited to any point value of 2 mmoL / mL, 4 mmoL / mL, 6 mmoL / mL, 8 mmoL / mL or 10 mmoL / mL or a range value between any two thereof. Limiting the concentration of magnesium chloride within a certain range can ensure the optimal activity of the enzyme in the reaction system, promote the efficient metabolism of vamolorone, and avoid enzyme inactivation or reduced reaction efficiency due to insufficient magnesium ions.

[0035] Further, in the incubated reaction system, the concentration of UDP-glucuronic acid is 2 to 10 mmoL / mL, including but not limited to any point value of 2 mmoL / mL, 4 mmoL / mL, 6 mmoL / mL, 8 mmoL / mL or 10 mmoL / mL or a range value between any two of them. The concentration of UDP-glucuronic acid is limited to a certain range, which ensures that the glucuronidation reaction is fully carried out, increases the amount of vamolorone metabolites, and improves the water solubility of metabolites, which is beneficial to the subsequent analysis and detection of metabolites.

[0036] Furthermore, in the incubated reaction system, the concentration of D-glucono-1,4-lactone is 2 to 10 mmoL / mL, including but not limited to any point value of 2 mmoL / mL, 4 mmoL / mL, 6 mmoL / mL, 8 mmoL / mL or 10 mmoL / mL or a range value between any two of them. By using an appropriate concentration of D-glucono-1,4-lactone, nonspecific reactions can be effectively inhibited, the specificity and reliability of metabolic reactions can be improved, and the accurate generation of metabolites can be ensured.

[0037] Furthermore, in the incubation reaction system, the concentration of liver microsomes is 0.5-2 mg / mL, including but not limited to any point value of 0.5 mg / mL, 0.8 mg / mL, 1.0 mg / mL, 1.3 mg / mL, 1.5 mg / mL, 1.8 mg / mL or 2 mg / mL or any range value between two thereof. Within this concentration range, the enzyme content in liver microsomes is moderate, which can simulate the metabolic environment in vivo and ensure sufficient metabolic rate, avoiding the substrate competition and enzyme saturation problems caused by excessive concentration.

[0038] Furthermore, in the incubation reaction system, the concentration of vamoglobin is 0.1-1 μg / mL, including but not limited to any point value of 0.1 μg / mL, 0.3 μg / mL, 0.5 μg / mL, 0.8 μg / mL or 1 μg / mL or any range value between two thereof. Within this concentration range, it is ensured that vamoglobin has sufficient substrates in the liver microsomes to participate in the metabolic reaction and generate sufficient metabolites for analysis, while avoiding nonspecific reactions and potential inhibitory effects caused by excessive concentrations.

[0039] In some specific embodiments, in the incubation reaction system: NADPH concentration is 5mmoL / mL, magnesium chloride concentration is 5mmoL / mL, UDPGA concentration is 5mmoL / mL, D-glucono-1.4-lactone concentration is 5mmoL / mL, liver microsome concentration is 1mg / mL, and vamoylolone concentration is 0.5μg / mL.

[0040] Furthermore, the liver microsomes include, but are not limited to, liver microsomes from mice, rats, dogs, rabbits, horses or humans. Liver microsomes from different sources can be used to implement the technical solution of the present invention.

[0041] Furthermore, the solvent of the reaction base solution includes a PBS buffer solution with a concentration of 0.1 M / L and a pH of 7.4.

[0042] Furthermore, the incubation temperature is 36-38°C, including but not limited to any point value of 36°C, 37°C or 38°C or a range value between any two of them.

[0043] Furthermore, the incubation time is 1 to 2 hours, including but not limited to any one of 1 hour, 1.2 hours, 1.4 hours, 1.6 hours, 1.8 hours or 2 hours, or a range between any two of them.

[0044] Under certain temperature and time conditions, the metabolic reaction of vamorosin can be fully completed, and the generated metabolites are stable and easy to detect.

[0045] Furthermore, the volume of the terminator added is 3 to 4 times the volume of the incubated reaction system, including but not limited to any point value of 3 times, 3.2 times, 3.4 times, 3.6 times, 3.8 times or 4 times, or a range value between any two of them.

[0046] Furthermore, the temperature of the terminator is 0°C

[0047] Furthermore, the terminator includes at least one of acetonitrile, methanol, toluene or dichloromethane.

[0048] Furthermore, the vortex time is 30 to 60 seconds, including but not limited to any point value of 30 seconds, 40 seconds, 50 seconds or 60 seconds or a range value between any two of them.

[0049] Furthermore, the centrifugal speed is 10000-20000 rpm, including but not limited to any point value of 10000 rpm, 11000 rpm, 12000 rpm, 13000 rpm, 14000 rpm, 15000 rpm, 16000 rpm, 17000 rpm, 18000 rpm, 19000 rpm or 20000 rpm or the range value between any two thereof.

[0050] Furthermore, the centrifugation time is 10 to 30 min, including but not limited to any one of 10 min, 15 min, 20 min, 25 min or 30 min or a range between any two of them.

[0051] Limiting the centrifugation speed and time within a certain range can improve the sensitivity and separation of the detection of vamocarb metabolites and effectively eliminate the interference of endogenous substances.

[0052] Furthermore, the conditions of the chromatographic detection are as follows:

[0053] Chromatographic column: ACE-EXCEL C18-PFP column (column length 150 mm × outer diameter 2.1 mm, inner diameter 3 μm); flow rate: 0.3-1 mL / min (for example, it can be, but not limited to, any point value of 0.3 mL / min, 0.4 mL / min, 0.5 mL / min, 0.6 mL / min, 0.7 mL / min, 0.8 mL / min, 0.9 mL / min or 1 mL / min or any range value between two); column temperature: 20-40°C (for example, it can be, but not limited to, any point value of 20°C, 25°C, 30°C, 35°C or 40°C or any range value between two); injection volume: 5-10 μL (for example, it can be, but not limited to any one of 5 μL, 6 μL, 7 μL, 8 μL, 9 μL or 10 μL, or a range between any two); mobile phase: phase A includes: 5-10 mM (for example, it can be, but not limited to any one of 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM, or a range between any two) ammonium formate, 0.05%-5% (for example, it can be, but not limited to any one of 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4% or 5%, or a range between any two) formic acid and water, and phase B is methanol. The present invention selects C18-PFP (pentafluorophenyl) chromatographic column, which combines the high hydrophilicity of C18 and the strong hydrophobicity of PFP, and can better separate metabolites with similar structures, especially those compounds with aromatic rings or polar groups. Compared with conventional C18 columns, the introduction of PFP improved the selectivity and separation of vamosauron and its metabolites, thereby improving the detection accuracy.

[0054] Furthermore, the elution procedure of the chromatographic detection is:

[0055] At 0 min, the volume ratio of mobile phase A to mobile phase B is 90-98:2-10, including but not limited to 90:10, 92:8, 94:6, 96:4 or 98:2;

[0056] At 1.5 min, the volume ratio of mobile phase A to mobile phase B was 98:2;

[0057] At 3.0 min, the volume ratio of mobile phase A to mobile phase B is 20-50:50-80, including but not limited to 20:80, 30:70, 40:60 or 50:50;

[0058] At 9.0 min, the volume ratio of mobile phase A to mobile phase B was 26:74;

[0059] At 12.0 min, the volume ratio of mobile phase A to mobile phase B was 5:95;

[0060] At 15.0 min, the volume ratio of mobile phase A to mobile phase B was 5:95;

[0061] At 15.1 min, the volume ratio of mobile phase A to mobile phase B was 98:2;

[0062] At 21.0 min, the volume ratio of mobile phase A to mobile phase B is 98-100:0-2, including but not limited to 98:2, 99:1 or 100:0.

[0063] Furthermore, the conditions for mass spectrometry detection are as follows:

[0064] Heated electrospray ionization source positive ion mode (HESI+), full scan mode (Full scan) and data dependent acquisition mode (DDA) were used. The full scan mode ensured that all metabolites in the low to high mass range could be detected, while the data dependent acquisition (DDA) mode further analyzed the metabolites of interest in depth. The spray voltage was +3.8 kV, the sheath gas and auxiliary gas pressures were 35 Pa and 15 Pa, the desolvation temperature was 350 ° C, the ion source temperature was 320 ° C, the mass error was <5 ppm, full scan mode: m / z 100-1000 Da (for example, it can be, but not limited to, any point value of 100 Da, 200 Da, 300 Da, 400 Da, 500 Da, 600 Da, 700 Da, 800 Da, 900 Da or 1000 Da or any range value between the two), resolution: 60000 (mass-to-charge ratio m / z = 200 Da), AGC target: 3e 6 ,dd-MS 2 Scan mode resolution 30000 (mass-to-charge ratio m / z = 200 Da), AGC target 1e 5 , collision energy gradient: 15-70 eV (for example, but not limited to 15 eV, 20 eV, 25 eV, 30 eV, 35 eV, 40 eV, 45 eV, 50 eV, 55 eV, 60 eV, 65 eV or 70 eV), isolation window m / z = 4-10 Da.

[0065] Furthermore, Compound Discoverer software was used to process and analyze the collected data, and Mass Frontier was used to perform detailed structural elucidation of the identified metabolites.

[0066] Instrument: Thermo Fisher UltiMate 3000 liquid chromatograph (Thermo Fisher, USA), equipped with binary high pressure gradient pump, online degasser, autosampler, column oven. The detector is Thermo Fisher Q-Exactive HF high resolution mass spectrometer (Thermo Fisher, USA), equipped with heated electrospray ion source (HESI), providing up to 240,000 resolution, mass range 50 to 6000 m / z.

[0067] Preparation of standard products and standard solutions:

[0068] Vamosone standard was purchased from Leyifeng Shanghai Pharmaceutical Technology Co., Ltd. (Shanghai, China).

[0069] PBS buffer solution: Accurately weigh 1.28 g of sodium dihydrogen phosphate monohydrate, 7.10 g of disodium hydrogen phosphate anhydrous, and 8.00 g of sodium chloride. Use a small amount of hydrochloric acid or sodium hydroxide to carefully adjust the pH value to 7.4. Add deionized water or distilled water to make up to 1000 mL, and store at 4°C for later use.

[0070] NADPH solution: Accurately weigh 148.28 mg and add PBS buffer solution to make up to 2 mL.

[0071] Magnesium chloride solution: Accurately weigh 190.42 mg and add PBS buffer solution to make up to 5 mL.

[0072] UDPGA solution: Accurately weigh 48.43 mg and add PBS buffer solution to make up to 2 mL.

[0073] D-Glucono-1,4-lactone solution: Accurately weigh 89.07 mg and add PBS buffer solution to make up to 10 mL.

[0074] Liver microsome solution: Accurately weigh 20 mg and add PBS buffer solution to make up to 1 mL.

[0075] Valmorolone solution: Accurately weigh 0.1 mg and add methanol solution to make up to 1 mL.

[0076] The embodiments of the present invention will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0077] Embodiment 1 to Embodiment 5

[0078] The NADPH regeneration system and the UGPDA regeneration system (Table 1) were used. The incubation systems and conditions of Examples 1-5 were shown in Table 1. The relative content of the metabolites of valmorolone was detected by HPLC-HRMS, and the metabolic rate was calculated. The calculation formula is as follows:

[0079] Metabolic rate = (total amount of metabolites produced / initial concentration) × 100%.

[0080] Method: In a culture tube operated on ice, add an appropriate amount of 0.1 mol / L PBS buffer solution with a pH of 7.4, then add an appropriate amount of thawed NADPH solution, magnesium chloride solution, UDPGA solution, D-glucono-1,4-lactone solution and vamosauron solution, and finally add an appropriate amount of PBS buffer solution to 200uL, vortex for 30s to mix, and obtain an incubation system. The final concentrations of liver microsomes, NADPH, UGPDA, magnesium chloride solution, D-glucono-1,4-lactone and vamosauron in the incubation system of Examples 1-5 are shown in Table 1.

[0081] Start the reaction: Incubate at a certain temperature and time (see Table 1), take out the culture tube, and quickly add 3 times the amount of glacial acetonitrile to terminate the metabolic reaction to obtain the metabolite of vamolorone.

[0082] The metabolites of vamosauron were vortexed for 30 s, centrifuged at 12,000 rpm for 10 min, and the supernatant was aspirated and transferred to a sample injection bottle for HPLC-HRMS detection.

[0083] Chromatographic conditions for the detection of metabolites of vamoylolone: ​​the chromatograph is a Thermo Fisher UltiMate 3000 liquid chromatograph (Thermo Fisher, USA), equipped with a binary high-pressure gradient pump, an online degasser, an automatic sampler, a chromatographic column oven, and the chromatographic column is an ACE-EXCEL C18-PFP chromatographic column (150 mm×2.1 mm, 3 μm); the mobile phase A is water containing 5 mM ammonium formate and 0.05% formic acid, and the mobile phase B is methanol, and the flow rate is 0.3 mL / min; the column temperature is 30° C.; the injection volume is 5 μL;

[0084] Mass spectrometry conditions for the detection of metabolites of vamolorone: The detector is a Thermo Fisher Q-Exactive HF high-resolution mass spectrometer (Thermo Fisher, USA), equipped with a heated electrospray ion source (HESI), providing up to 240,000 resolution, and a mass range of 50 to 6000 m / z. Mass spectrometry detection conditions: heated electrospray ionization source positive ion mode (HESI+); full scan (Full scan) and data-dependent acquisition (DDA); spray voltage is +3.8 kV; sheath gas and auxiliary gas pressures are 35 Pa and 15 Pa, respectively; desolvation temperature is 350 ° C; ion source temperature is 320 ° C; mass error <5 ppm; full scan mass range m / z 100-1000 Da; resolution is 60,000 (m / z 200 Da); AGC target is 3e 6 ;dd-MS 2 Scan mode resolution is 30,000 (m / z 200); AGC target is 1e 5 The collision energy gradient was 15 eV, 40 eV and 70 eV; the isolation window was m / z 4. The residual content of vamorosin after metabolism was detected by extracting the accurate molecular ion of the parent ion of vamorosin, and the metabolic rate was calculated. The calculation results are shown in Table 1.

[0085] Table 1 Metabolic reaction conditions and metabolic rate of valmorolone in liver microsomes

[0086]

[0087] As can be seen from Table 1, Example 4 is metabolized more, with a metabolic rate of 26.5%. Example 4 performs better, and the sample of Example 4 is selected for the detection and analysis of metabolites.

[0088] Example 6

[0089] The only difference between this comparative example and Example 4 is that the concentration of liver microsomes in the incubation system is 3 mg / mL.

[0090] Example 7

[0091] The difference between this comparative example and Example 4 is that the concentration of nicotinamide adenine dinucleotide phosphate in the incubation system is 1 mmoL / mL.

[0092] Example 8

[0093] The difference between this comparative example and Example 4 is that the concentration of magnesium chloride in the incubation system is 12 mmol / mL.

[0094] Example 9

[0095] The difference between this comparative example and Example 4 is that the concentration of UDP-glucuronic acid in the incubation system is 13 mmol / mL.

[0096] Example 10

[0097] The difference between this comparative example and Example 4 is that the concentration of D-glucono-1,4-lactone in the incubation system is 0.5 mmol / mL.

[0098] Table 2 Metabolic rate of Examples 6 to 10

[0099] Example 6 7 8 9 10 Surplus rate (%) 78.2 77.5 84.5 79.8 77.6 Metabolic rate (%) 21.8 22.5 25.5 20.2 22.4

[0100] Embodiment 11

[0101] The metabolites of vamosaurus obtained in Example 4 were detected and analyzed.

[0102] Simultaneous control trials:

[0103] Control group 1: In a system with NADPH concentration of 5 mmol / L, magnesium chloride solution concentration of 5 mmol / L, UGPDA concentration of 5 mmol / L, D-glucono-1,4-lactone concentration of 5 mmol / L, and liver microsome concentration of 1 mg / mL, no valmorolone concentration was added.

[0104] Control group 2: In the system with NADPH concentration of 5 mmol / L, magnesium chloride solution concentration of 5 mmol / L, UGPDA concentration of 5 mmol / L, D-glucono-1,4-lactone concentration of 5 mmol / L, and vamosolone concentration of 0.5 μg / mL, no liver microsomes were added.

[0105] The experimental process and sample treatment of control group 1 and control group 2 were consistent with those of experimental group 4.

[0106] The specific conditions for the detection of vamosauron metabolites are as follows:

[0107] Chromatographic conditions:

[0108] Chromatographic column: ACE-EXCEL C18-PFP column (150 mm × 2.1 mm, 3 μm);

[0109] Flow rate: 0.3 mL / min;

[0110] Column temperature: 30°C;

[0111] Injection volume: 5 μL;

[0112] Mobile phase: Phase A: water containing 5 mM ammonium formate and 0.05% formic acid, Phase B: methanol, gradient program as shown in Table 3.

[0113] Table 3 Elution program

[0114] Time (min) A(%) B(%) 0 98% 2% 1.5 98% 2% 3.0 50% 50% 9.0 26% 74% 12.0 5% 95% 15.0 5% 95% 15.1 98% 2% 21.0 98% 2%

[0115] Mass spectrometry conditions:

[0116] Ionization mode: heated electrospray ionization source positive ion mode (HESI+);

[0117] Scanning modes: Full scan and data dependent acquisition (DDA);

[0118] Spray voltage: +3.8kV;

[0119] Sheath gas and auxiliary gas pressure: 35Pa and 15Pa;

[0120] Desolventization temperature: 350°C;

[0121] Ion source temperature: 320°C;

[0122] Mass error: <5ppm;

[0123] Full scan mode: m / z 100~1000Da;

[0124] Resolution: 60,000 (m / z 200Da);

[0125] AGC target: 3e 6 ;

[0126] dd-MS 2 Scan mode resolution: 30,000 (m / z 200);

[0127] AGC target: 1e 5 ;

[0128] Collision energy gradient: 15eV, 40eV and 70eV;

[0129] Isolation window: m / z 4.

[0130] Sample Analysis:

[0131] In data analysis, Compound Discoverer 3.3 software was used to read and screen the raw data collected from all samples, as well as to identify the total ion flow and selected ion chromatograms, to screen out the newly added chromatographic peaks, which were metabolites, and to deduce the structural formula of the metabolites through high-resolution primary mass spectrometry data combined with the metabolic reactions and molecular formulas given by the software. The parent ions and fragment ions in the samples were read using Mass Frontier 8.1 software, and the possible fragment information given by the software for deducing the compound structure was combined, and the structure was supported by comparing the two and the literature.

[0132] Figure 1The total ion current chromatogram of liver microsomes and incubation system (without vamorolone) is shown in Figure 1. Figure 2 This is the total ion current chromatogram of vamosauron and incubation system (without liver microsomes). Figure 3 This is the total ion current chromatogram of vamosone after conversion in the liver microsome incubation system.

[0133] The Compound Discoverer data analysis software Figure 1 , Figure 2 and Figure 3 The newly added chromatographic peaks were screened out, which were the metabolites of vamorolong in the transformation of liver microsomes. The results showed that 12 metabolites were detected after vamorolong was metabolized in liver microsomes. The structural formula of the metabolite was deduced by combining the high-resolution primary mass spectrometry data with the metabolic reaction and molecular formula given by the software. The parent ion and fragment ion in the sample were read by the software Mass Frontier 8.1, and the possible fragment information given by the software for deducing the compound structure was combined. The structure was supported by comparing the two and the literature. The 12 metabolites were deduced and confirmed, of which 11 metabolites were found for the first time in liver microsome transformation ( Figure 4 ).

[0134] A total of 12 metabolites of vamorotolone were detected in the metabolic system of liver microsomes (as shown in Table 4), and their structures were analyzed and identified, including 10 phase I metabolites (M1-M8, iso-M1, iso-M3) and 2 phase II metabolites (M9-M10). M1 and iso-M1 are the result of the reduction reaction of vamorotolone in liver microsomes, and their molecular ion peaks [M+H] + They were m / z 359.2212 and m / z 359.2213 respectively. 1 and MS 2 Mass spectrometry analysis confirmed that m / z 341.2108 and m / z 323.2002 were fragment ions after removing one hydroxyl group and two hydroxyl groups, respectively, and m / z 173.0961 and m / z 171.0804 were fragment ions after removing the C ring and D ring. The molecular ion peak of M2 [M+H] + m / z 355.1902 is the dehydrogenation reaction of the parent drug, m / z 237.1273 is the fragment ion produced after the D-ring cleavage, and m / z 337.1791 and m / z 319.1962 are the fragment ions produced after losing one and two hydroxyl groups respectively. M4 molecular ion peak [M+H] +The m / z is 373.2013, which is the hydroxy metabolite formed by the oxidation reaction of the parent drug. The m / z 355.1904 and m / z 337.1798 are the fragment ions of M4 losing one and two hydroxyl groups, respectively. The M5 fragment is obviously different from M1, lacking m / z 173.0961 and m / z 171.0804 ions, which is formed by the reduction reaction on the A ring of the parent drug. The m / z 341.2108 and m / z 323.2007 are the fragment ions produced after losing one and two hydroxyl groups, respectively. M6 and M7 have the same molecular ion peak [M+H]m / z 371.1850 at different retention times and are identified as positional isomers, which are formed by further dehydrogenation after the parent drug is oxidized. The molecular ion peak [M+H] of M8 is m / z 339.1953, which is the result of a further dehydrogenation reaction after the parent drug undergoes dehydroxylation, and m / z 321.1848 is a fragment ion formed after removing a hydroxyl group. M9 and M10 are two phase II glucuronic acid metabolites of vamolorone, and m / z 357.2058 is a fragment ion formed after M9 and M10 lose glucuronide, and the remaining fragment information is consistent with the parent drug compound. The method of the present invention can be used to more accurately infer the structure of metabolites, which is of great significance for in-depth research on active pharmaceutical ingredients and their mechanisms of action.

[0135] Table 4 The 12 metabolites of valmorolone in liver microsomes

[0136]

[0137]

[0138] In summary, the method of the present invention can more accurately infer the structure of metabolites, which is of great significance for in-depth research on active drug products and their mechanisms of action. Figure 5 The chemical structure of the metabolite of vamoglobin in the liver microsome incubation system deduced by the above method.

[0139] Although the present invention has been illustrated and described with specific embodiments, it should be appreciated that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Those skilled in the art should understand that the technical solutions described in the above embodiments may be modified, or some or all of the technical features thereof may be replaced by equivalents without departing from the spirit and scope of the present invention. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention. Therefore, this means that all such replacements and modifications within the scope of the present invention are included in the appended claims.

Claims

1. A method for determining the metabolites of valmorolone in liver microsomes, characterized in that: The following steps are involved: (a) adding vamosaurus to the reaction base solution for incubation; Adding a terminator to the reaction system after the incubation to obtain a vamosaurus metabolite; The reaction base solution includes: nicotinamide adenine dinucleotide phosphate, magnesium chloride, uridine diphosphate glucuronic acid, D-glucono-1.4-lactone and liver microsomes; (b) vortexing and centrifuging the vamosaurus metabolite to collect the supernatant; (c) subjecting the supernatant to chromatography and mass spectrometry; (d) Identification of metabolites.

2. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: In the incubation reaction system, the concentration of nicotinamide adenine dinucleotide phosphate is 2-10 mmol / mL.

3. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: In the incubation reaction system, the concentration of magnesium chloride is 2-10 mmol / mL.

4. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: In the incubation reaction system, the concentration of UDP-glucuronic acid is 2-10 mmol / mL.

5. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: In the incubation reaction system, the concentration of D-glucono-1,4-lactone is 2 to 10 mmol / mL.

6. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: In the incubation reaction system, the concentration of liver microsomes is 0.5-2 mg / mL.

7. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: In the incubation reaction system, the concentration of vamosone is 0.1-1 μg / mL.

8. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: The conditions of the chromatographic detection are as follows: Chromatographic column: ACE-EXCEL C18-PFP column; flow rate: 0.3-1 mL / min; column temperature: 20-40°C; injection volume: 5-10 μL; Mobile phase: Phase A includes: 5-10 mM ammonium formate, 0.05%-5% formic acid and water, and phase B is methanol.

9. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: The elution procedure of the chromatographic detection is as follows: at 0 min, the volume ratio of mobile phase A to mobile phase B is 90-98:2-10; at 1.5 min, the volume ratio of mobile phase A to mobile phase B is 98:2; at 3.0 min, the volume ratio of mobile phase A to mobile phase B is 20-50:50-80; at 9.0 min, the volume ratio of mobile phase A to mobile phase B is 26:74; at 12.0 min, the volume ratio of mobile phase A to mobile phase B is 5:95; at 15.0 min, the volume ratio of mobile phase A to mobile phase B is 5:95; at 15.1 min, the volume ratio of mobile phase A to mobile phase B is 98:2; at 21.0 min, the volume ratio of mobile phase A to mobile phase B is 98-100:0-2.

10. The method for determining the metabolites of valmorolone in liver microsomes according to claim 1, characterized in that: Includes at least one of the following technical features: (1) The mass spectrometer adopts a full scan mode and a data-dependent acquisition mode; (2) the incubation temperature is 36-38° C.; (3) The incubation time is 1 to 2 hours; (4) The terminator comprises at least one of acetonitrile, methanol, toluene or dichloromethane.